Search results
Showing 346 to 360 of 374 results for depression
Evidence-based recommendations on belantamab mafodotin (Blenrep) with pomalidomide and dexamethasone for previously treated multiple myeloma in adults.
Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over.
Evidence standards framework for digital health technologies (ECD7)
This document describes an evidence standards framework (ESF) for digital health technologies (DHTs). It was developed by NICE between June 2018 and February 2019 in collaboration with NHS England, Public Health England and MedCity. The work was commissioned by NHS England
This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on overweight and obesity. It does not cover pregnancy.
Show all sections
Sections for NG246
This guideline covers the planning, delivery and review of social work interventions for adults who have complex needs. It promotes ways for social work professionals, other care staff and people with complex needs to work together to make decisions about care and support.
Evidence-based recommendations on lead-I electrocardiogram (ECG) devices (imPulse, Kardia Mobile, MyDiagnostick and Zenicor-ECG) for detecting symptomatic atrial fibrillation using single time point testing in primary care.
Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults.
Disease-specific reference case extension: management of overweight and obesity in adults (PMG50)
This NICE disease-specific reference case extension describes standardised methods for health economic evaluations of interventions for managing overweight and obesity in adults. For further details on developing and implementing disease-specific reference case extensions, see NICE’s position statement on use of disease-specific reference models in economic evaluations
Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for treating severe sickle cell disease in people 12 years and over.
Tobacco: preventing uptake, promoting quitting and treating dependence (NG209)
This guideline covers support to stop smoking for everyone aged 12 and over, and help to reduce people's harm from smoking if they are not ready to stop in one go. It also covers ways to prevent children, young people and young adults aged 24 and under from taking up smoking.
The NICE public health guidance development process (third edition) (PMG5)
This manual describes how public health guidance is produced, and explains the stages of guidance development, the different activities, roles and responsibilities of different groups of people involved at different stages
This manual explains the processes and methods used to develop and update NICE guidelines, the guidance that NICE develops covering topics across clinical care (in primary, secondary and community care settings), social care and public health. For more information on the other types of NICE guidance and advice (including technology appraisal guidance), see about NICE
This guide provides an overview of the principles and methods of health technology assessment and appraisal within the context of the NICE appraisal process
This guideline covers support for disabled children and young people with severe complex needs, from birth to 25 years. It aims to encourage education, health and social care services to work together and provide more coordinated support to children and young people, and their families and carers.
Show all sections
Sections for NG213
- Overview
- Recommendations on support for all disabled children and young people with severe complex needs
- Recommendations on specialist support for disabled children and young people with particular needs
- Recommendations on service organisation, integration and commissioning
- Terms used in this guideline
- Recommendations for research
- Rationale and impact for recommendations on supporting all disabled children and young people with severe complex needs
- Rationale and impact for recommendations on specialist support for disabled children and young people with particular needs
NICE technology appraisal and highly specialised technologies guidance: the manual (PMG36)
This guide describes the methods and processes, including expected timescales, that NICE follows when carrying out health technology evaluations. The methods and processes are designed to produce robust guidance for the NHS in an open, transparent and timely way, with appropriate contribution from stakeholders. Organisations invited to contribute to health technology evaluation development should read this manual in conjunction with the NICE health technology evaluation topic selection: the manual. All documents are available on the NICE website